Corbus Pharmaceuticals Holdings, Inc. - Common Stock (CRBP)
6.0300
+0.1100 (1.86%)
NASDAQ · Last Trade: Apr 18th, 4:02 AM EDT
Detailed Quote
Previous Close | 5.920 |
---|---|
Open | 5.890 |
Bid | 5.200 |
Ask | 6.100 |
Day's Range | 5.780 - 6.140 |
52 Week Range | 4.640 - 61.90 |
Volume | 121,749 |
Market Cap | 26.67M |
PE Ratio (TTM) | -1.657 |
EPS (TTM) | -3.6 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 218,595 |
Chart
About Corbus Pharmaceuticals Holdings, Inc. - Common Stock (CRBP)
Corbus Pharmaceuticals Holdings Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies to treat rare and chronic inflammatory diseases. The company specializes in cannabinoid-based treatments and aims to address unmet medical needs through its research and development efforts. Corbus is dedicated to advancing its pipeline of drug candidates, leveraging its expertise in pharmaceuticals to improve patient outcomes and enhance the quality of life for those suffering from challenging health conditions. Read More
News & Press Releases
Via Benzinga · April 15, 2025
Via Benzinga · April 1, 2025

Corbus Pharmaceuticals presented Phase 1 data on CRB-701 at ASCO GU, showing safety, tolerability, and responses across multiple tumor types.
Via Benzinga · February 14, 2025

Via Benzinga · January 20, 2025

Via Benzinga · October 8, 2024

Viking Therapeutics is an upstart in the weight-loss drugs space. But it's catching attention.
Via Investor's Business Daily · October 4, 2024

Via Benzinga · September 25, 2024

Corbus Pharmaceuticals received buy ratings from H.C. Wainwright and Oppenheimer, citing the company's diversified pipeline.
Via Benzinga · September 23, 2024